Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Next Previous
Trial Profile

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Ipilimumab (Primary) ; Irinotecan (Primary) ; NEO-212 (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Regorafenib (Primary)
  • Indications Astrocytoma; Brain metastases; Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NEONC Technologies

Most Recent Events

  • 29 Nov 2023 Status changed from not yet recruiting to recruiting.
  • 18 Oct 2023 Planned initiation date changed from 1 Oct 2023 to 1 Nov 2023.
  • 26 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top